RUNX1 and acute myeloid leukemia: One diagnostic AML sample, characterized by a KMT2A rearrangement, lost the FLT3 TKD mutation and gained a NRAS mutation at relapse; one AML relapsed sample with a NUP98-NSD1 fusion, gained only a new mutation in Runx1 and RIT1 in a subsequent refractory sample.